.After a handful of years in biotech, Mike Quigley, Ph.D., is going back to the pharma layer, occupying the top science area at Sanofi.Quigley will begin Sept. 30 as the French Big Pharma's main medical policeman and also international head of study, Sanofi told Brutal Biotech in an emailed claim.Quigley is actually changing Frank Nestle, M.D., who left behind Sanofi this springtime amidst a global overhaul of the company's R&D system. Nestle, that devoted 8 years with the pharma, jumped over to Deerfield Monitoring, where he currently acts as a partner on the rehabs crew as well as chief executive officer of the company's restorative revelation and progression operations.
Quigley is going to join Sanofi from a San Francisco-based biotech that resides in secrecy, according to his LinkedIn account. He's currently detailed as the firm's co-founder, president as well as chief executive officer.Because August 2021, Quigley has acted as an endeavor partner at SV Wellness Investors, a health care fund supervisor with present assets in biotechs such as BioAge, Cerevance, Dualitas Therapies and also Nimbus Therapies, to name a few. Quigley formerly held the leading location at Dualitas, a biotech that remains in stealth, depending on to STAT.The future Sanofi forerunner likewise previously helmed Therini Bio, an immunotherapy biotech operating to develop treatments for neurodegenerative ailments steered through general problems.Just before investing the final handful of years in biotech, Quigley has an also longer performance history in Big Pharma, very most lately functioning as Gilead's senior vice president of research study the field of biology until the summertime of 2021. Prior to that, he appeared much more than 4 years throughout numerous leadership jobs at Bristol Myers Squibb and also worked as a scientific supervisor at Johnson & Johnson's Janssen upper arm just before that.Sanofi pointed out Quigley's objective in his new role would be to "optimize our chance of excellence via optimum partnerships around our institution and also beyond, delivering best-in-class technology in addition to establishing and sourcing brand-new industry-leading ability along with a devotion to range," according to an internal memorandum gotten through STAT.